You are currently viewing Teste de Antígeno MeriScreen
Meriscreen covid 19 antigen

Teste de Antígeno MeriScreen

Princípio

O Teste de detecção de antígeno COVID-19 é um teste de imunoensaio para a detecção rápida e qualitativa da infecção por SARS-CoV-2 em espécimes de esfregaço. Os anticorpos monoclonais anti-SARS-CoV-2 são revestidos na região da linha de teste. Os antígenos de SARS-CoV-2, se presentes nas amostras, irão interagir com os anticorpos monoclonais antiSARS-CoV-2 conjugados com o conjugado de ouro, formando o complexo antígeno-anticorpo. Este complexo migra na membrana por ação capilar, onde será capturado pelo anticorpo monoclonal anti-SARS-CoV-2 revestido na linha teste. Uma linha de teste colorida seria visível na janela de resultados se os antígenos SARS-CoV-2 estivessem presentes na amostra. A intensidade da linha de teste colorida irá variar dependendo da quantidade de antígeno SARS-CoV-2 presente na amostra.

meriscreen antigen test kit
meriscreen antigen test kit

SKU: NCTCAG-01

DISPONIBILIDADE: Esgotado

REMESSA: 1 ou 2 dias úteis de graça

TAMANHO: 25 testes / kit

SENSIBILIDADE: 96,6%

ESPECIFICIDADE: 100%

meriscreen-covid-19-antigen-test-kit-pack
meriscreen-covid-19-antigen-test-kit-pack

KIT DE TESTE DE ANTÍGENO MERISCREEN COVID-19

O teste de detecção de antígeno MeriScreen COVID-19 é um teste de ensaio imunocromatográfico rápido para a detecção qualitativa do antígeno SARS-CoV-2 em uma amostra de esfregaço nasofaríngea de um corpo humano.

  • REVESTIDO COM ANTICORPO ANTI-SARS-COV-2 MONOCLONAL ALTAMENTE PURIFICADO
  • RESULTADOS EM 20 MINUTOS
  • A AMOSTRA É SWAB NASOFARÍNGICO
  • SENSIBILIDADE: 96,6%
  • ESPECIFICIDADE: 100%

Observação:
 Os kits listados abaixo são validados apenas com o número de lote mencionado. A responsabilidade pela
consistência lote a lote não é do ICMR.
 Critérios mínimos de aceitação de sensibilidade e especificidade dos kits de teste Rapid Ag:
 Validado como um teste de ponto de cuidado (POCT) sem transporte para uma configuração de laboratório Sensibilidade: 50% e acima
Especificidade: 95% e acima
 Validado em uma configuração de laboratório com amostras coletados em meio de transporte viral (VTM) –
Sensibilidade: 70% e acima
Especificidade: 99% e acima
 Testes rápidos baseados em antígenos que são aprovados pela FDA dos EUA podem ser usados ​​diretamente após a devida aprovação de comercialização do DCGI.

meriscreen-covid-19-antigen-test-kit
meriscreen-covid-19-antigen-test-kit

Breve metodologia de uso do COVID-19 Ag Respi-Strip (CorisBioConcept):
1. O swab nasofaríngeo e / ou orofaríngeo será coletado do paciente suspeito COVID-19 em meio de transporte viral (VTM).
2. O swab coletado em VTM será levado ao laboratório em condições apropriadas da cadeia de frio.
3. Assim que a amostra for levada para o laboratório, ela precisará ser manuseada em um gabinete de nível BSL-2 para alíquotas, colocando em tampão de lise e carregando a tira de teste.
 As etapas 1 e 2 serão realizadas de acordo com a prática padrão seguida para coleta e transporte de amostras para o teste COVID-19 RT-PCR.
 A etapa 3 deverá ser realizada de acordo com as instruções do fabricante fornecidas com o kit de teste.

 

COVID-19 IgG/IgM Rapid Test Kit

UNCOV-20 20T/kit
EUR 155
Description: COVID-19 IgG/IgM Rapid Test (Serum/Plasma/Whole Blood) is a qualitative membrane-based immunoassay for the detection of COVID-19 antibodies in serum, plasma, or whole blood. This test consists of two test lines, an IgG line and an IgM line, which is pre-coated with two mouse anti-human monoclonal antibodies separately. During testing, the sample reacts with COVID-19 antigen-coated on conjugated pad. As the complex continues to travel up the strip, the anti-COVID-19 IgM antibodies are bound on the IgM line, and the anti-COVID-19 IgG antibodies are bound on the IgG line. The control(C)line appears when sample has flowed through the strip. The presence of anti-COVID-19 IgM and/or IgG will be indicated by a visible test line in the IgM and IgG region. To serve as a procedural control, the control line should always appear if the test procedure is performed properly and the reagents are working as intended.

SARS-CoV-2 (COVID-19) Spike Antibody

3525-002mg 0.02 mg
EUR 171.82
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Spike Antibody

3525-01mg 0.1 mg
EUR 436.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6).

SARS-CoV-2 (COVID-19) Envelope Antibody

3531-002mg 0.02 mg
EUR 171.82
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).

SARS-CoV-2 (COVID-19) Envelope Antibody

3531-01mg 0.1 mg
EUR 436.42
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one alpha-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication (3).

SARS-CoV-2 (COVID-19) NSP7 Peptide

9155P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP7 Peptide

SARS-CoV-2 (COVID-19) Membrane Peptide

9157P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Membrane Peptide

SARS-CoV-2 (COVID-19) NSP8 Peptide

9159P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide

SARS-CoV-2 (COVID-19) NSP9 Peptide

9161P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide

SARS-CoV-2 (COVID-19) NSP9 Peptide

9163P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP9 Peptide

SARS-CoV-2 (COVID-19) Membrane Peptide

9165P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Membrane Peptide

SARS-CoV-2 (COVID-19) NSP8 Peptide

9167P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP8 Peptide

SARS-CoV-2 (COVID-19) Envelope Peptide

9169P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) Envelope Peptide

SARS-CoV-2 (COVID-19) NSP2 Peptide

9171P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide

SARS-CoV-2 (COVID-19) NSP2 Peptide

9173P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP2 Peptide

SARS-CoV-2 (COVID-19) NSP4 Peptide

9175P 0.05 mg
EUR 196.25
Description: SARS-CoV-2 (COVID-19) NSP4 Peptide

Leave a Reply